ITOCD Event 2010

Agenda

Targeting Tumor Angiogenesis: Molecular Biology and Clinical Practice

Chairs: R. Herrmann, Basel / N. Saijo, Tokyo

 

Biomarkers profile and clinical factors in selecting patients

A.B. Sandler, Portland

Presentation PDF

 

Imaging in targeted therapy

C. Fink, Mannheim

Presentation PDF

 

Management of toxicity of anti-angiogenic/anti-EGFR agents

J. Heymach, Houston

Presentation PDF

 

Integrin inhibitors

S. Peters, Lausanne

Presentation PDF

 

Vascular disrupting agents

J.Y. Doulliard, Nantes

Presentation PDF

 

Anti-angiogenic TKI’s

U. Gatzemeier, Großhansdorf

Presentation PDF

 

Molecular biology

E. Voest, Utrecht

 

Novel Agents I

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris

 

Heat shock protein targeting agents

K. O’Byrne, Dublin

Presentation PDF

 

Histone deacetylase inhibitors

S. Ramalingam, Atlanta

Presentation PDF

 

PARP1-inhibitors

J.-C. Soria, Paris

Presentation PDF

 

Dendritic cell recruitors and activators

A. Y. Chang, Singapore

Presentation PDF

 

Vaccine therapy

J. Vansteenkiste, Leuven

Presentation PDF

 

Pro-apoptotic agents

F. R. Khuri, Atlanta

Presentation PDF

 

Mannheim Lilly Oncology Lecture

 

Targeted therapy: how to clinically develop new agents and treatment strategies based on pre-clinical information

P. Bunn, Denver

Presentation PDF

 

Targeting the Epidermal Growth Factor Receptor (EGFR): Molecular Biology and Clinical Practice

Chairs: N.Thatcher, Manchester / K. Syrigos, Athens

 

Molecular biology of the EGFR-pathway

A. F. Gazdar, Dallas

Presentation PDF

 

Clinical and molecular predictors of EGFR-TKI sensitivity

F. A. Shepherd, Toronto

Presentation PDF

 

Mechanism of drug resistance and how to overcome first generation EGFR- TKI failure

P. A. Jänne, Boston

Presentation PDF

 

EGFR-TKI first-line therapy: diagnostic assessment and drug selection

T. Mok, Hong Kong

Presentation PDF

 

EGFR-assessment in prospective clinical trials

R. Dziadziusko, Gdansk

Presentation PDF

 

Treatment duration and sequencing of EGFR-TKI inhibitors

F. Cappuzzo, Livorno

Presentation PDF

 

EGFR-targeting antibodies: clinical and molecular sensitivity predictors

R. Pirker, Vienna

Presentation PDF

 

EGFR-targeting antibodies in combination with radiotherapy

F. Mornex, Lyon

Presentation PDF

 

NSCLC: Relevance of Treatment Prediction by Histology for Early and Advanced Disease

Chairs: F. Blackhall, Manchester / C. Manegold, Mannheim

 

Relevance of TS testing: British experience

K. Kerr, Aberdeen

Presentation PDF

 

Pharmacogenomic guided treatment strategies for early NSCLC

G. V. Scagliotti, Torino

Presentation PDF

 

Pemetrexed (Alimta therapy): duration and frequency

C. Belani, Hersey

Presentation PDF

 

Gene Expression/Tumor Histology Guided Therapy

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok

 

Molecular basis

H. Allgayer, Mannheim

Presentation PDF

 

Proteomics and outcome prediction

D. P. Carbone, Nashville

 

Rationale for Genomic Guided Molecular Therapy in Lung Cancer

A. Potti, Durham / N. Ready, Durham

Presentation PDF

 

MicroRNA signatures and outcome prediction

P.-C. Yang, Taiwan

Presentation PDF

 

TS-expression and sensitivity to anti-folates

G. V. Scagliotti, Torino

Presentation PDF

 

ERCC1, RRM1, and BRCA1-gene expression and outcome prediction

G. Bepler, Detroit

Presentation PDF

 

Tumor histology and clinical outcome

C. Manegold, Mannheim

Presentation PDF

 

Novel Agents II

Chairs: P. Postmus, Amsterdam / J. S. Lee, Seoul

 

ACT, MAPK, MEK-inhibitors

A. Adjei, Buffalo

Presentation PDF

 

ALK, MET-inhibitors

R. Stahel, Zürich

Presentation PDF

 

SRC-targeting agents

O. Gautschi, Bern

Presentation PDF

 

m-Tor-inhibitors

L. Crinò, Perugia

Presentation PDF

 

Insulin growth factor receptor targeting agents

L. Paz-Ares, Sevilla

Presentation PDF

 

Tabacco Control and Lung Cancer Prevention

(supported by an Eli-Lilly unrestricted educational grant)

Chairs: L.R. Pilz, Heidelberg / K. Park, Seoul

 

WHO perspectives in reducing lung cancer mortality

A. Ullrich, Geneva

Presentation PDF

 

Tobacco control policy in Poland

J. Jassem, Gdansk

Presentation PDF

 

Smoking cessation in women

C. M. Dresler, Littler Rock

Presentation PDF

 

Female gender as a prognostic and predictive factor

S. Novello, Torino

Presentation PDF

 

New targets for chemoprevention

Y. E. Miller, Denver

Presentation PDF

 

Chemoprevention of high risk patient populations

N. van Zandwijk, Sydney

Presentation PDF

 

2010 Challenges in Thoracic Oncology I

Chairs: D. H. Grunenwald, Paris / C. Zhou, Shanghai

 

Implications of the new TNM system for the surgical management of early stage lung cancer

P. Goldstraw, London

Presentation PDF

 

Implications of the new TNM system for modern imaging

S. Schönberg, Mannheim / C. Fink, Mannheim

Presentation PDF

 

Minimally invasive non-surgical methods for staging lung cancer

F. Herth, Heidelberg

Presentation PDF

 

Adjuvant chemotherapy

B. Besse, Paris

Presentation PDF

 

Induction chemotherapy

P. van Schil, Antwerp

Presentation PDF

 

Advanced NSCLC: maintenance therapy

C. Belani, Hersey

Presentation PDF

 

2010 Challenges in Thoracic Oncology II

Chairs: P. Hohenberger, Mannheim / E. Smit, Amsterdam

 

Stereotactic radiation therapy for stage I NSCLC

F. Wenz, Mannheim

Presentation PDF

 

Chemo-radiation

D. de Ruysscher, Maastricht

Presentation PDF

 

Is thymic carcinoma a specific entity?

A. Marx, Mannheim / P. Ströbel, Mannheim

Presentation PDF

 

Malignant pleural mesothelioma: extension of surgery

W. Weder, Zurich

Presentation PDF

 

Malignant pleural mesothelioma: new drug development

D. Fennell, Belfast

Presentation PDF

 

SCLC: Combined modality therapy in limited stage disease

A. Ardizzoni, Parma

Presentation PDF

 

 

About us

PEKKIP Congress GmbH is responsible for planning, executing and following up high-class medical conventions, training courses, advisory boards and networking events.

A brief history overview

Did you miss one of our events or would like to review some of the information from past conventions? It doesn’t get easier than this. Simply read through all the details here.

There’s always someone around to serve you. 

Do you have questions about our offers or need more information on one of our events? Give us a ring on +49 (0)6221 655 700, and we will be happy to help you.

Additional ways to contact us